The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

An application of Radix Gentianae Macrophyllae, a Radix Gentianae Macrophyllae extract, and a Radix Gentianae Macrophyllae monomer compound or a salt, an ester, an isomer, a solvate, and a derivative thereof in the preparation of an acaricidal product. The Radix Gentianae Macrophyllae monomer compound is selected from one or more of gentiopicrin, loganic acid, sweroside, roburic acid, scopoletin, rubimaillin, and swertiamarin.

An application of Radix Gentianae Macrophyllae, a Radix Gentianae Macrophyllae extract, and a Radix Gentianae Macrophyllae monomer compound or a salt, an ester, an isomer, a solvate, and a derivative thereof in the preparation of an acaricidal product. The Radix Gentianae Macrophyllae monomer compound is selected from one or more of gentiopicrin, loganic acid, sweroside, roburic acid, scopoletin, rubimaillin, and swertiamarin.

Use of dandelion and monomer compounds thereof for preparing products for killing mites. Dandelion can reduce the survival time of mites. The dandelion monomers, especially taraxerol, diosmetin and taraxasterol acetate, can significantly shorten the survival time of demodex, and can be used for preparing products for killing and inhibiting mites.

Use of dandelion and monomer compounds thereof for preparing products for killing mites. Dandelion can reduce the survival time of mites. The dandelion monomers, especially taraxerol, diosmetin and taraxasterol acetate, can significantly shorten the survival time of demodex, and can be used for preparing products for killing and inhibiting mites.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

According to an aspect of the present application, a composition for controlling a target pest comprises 0.1% to 4% isopropyl myristate, 0.1% to 15% thyme oil white, 0.1% to 2% geraniol, and at least one additional active ingredient selected from thymyl acetate, linalyl acetate, amyl butyrate, anise star oil, black seed oil, p-cymene, linalool, d-limonene, isopropyl myristate, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and wintergreen oil. The composition causes synergistic control of the target pest.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.